Evotec AG | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
85,938.00
89,496.00
127,677.00
164,507.00
257,630.00
375,405
Cost of Goods Sold (COGS) incl. D&A
57,937.00
62,580.00
92,550.00
105,953.00
175,062.00
263,389
Gross Income
28,001.00
26,916.00
35,127.00
58,554.00
82,568.00
112,016
SG&A Expense
26,261.00
30,394.00
42,618.00
45,121.00
56,715.00
96,845
EBIT
1,740.00
1,978.00
2,584.00
-
25,853.00
15,171
Unusual Expense
22,743.00
4,773.00
9,243.00
6,577.00
4,844.00
2,545
Non Operating Income/Expense
2,491.00
1,572.00
24,282.00
25,958.00
7,083.00
40,759
Interest Expense
415.00
449.00
497.00
352.00
879.00
2,467
Pretax Income
23,648.00
5,159.00
12,491.00
33,325.00
28,116.00
51,816
Income Tax
1,785.00
1,819.00
4,025.00
6,111.00
2,334.00
36,339
Equity in Affiliates
-
-
-
375.00
1,783.00
4,099
Consolidated Net Income
25,433.00
6,978.00
16,516.00
26,839.00
23,999.00
84,056
Net Income
25,433.00
6,978.00
16,516.00
27,530.00
24,257.00
84,172
Net Income After Extraordinaries
25,433.00
6,978.00
16,516.00
27,530.00
24,257.00
84,172
Net Income Available to Common
25,433.00
6,978.00
16,516.00
27,530.00
24,257.00
84,172
EPS (Basic)
0.21
0.05
0.13
0.21
0.17
0.57
Basic Shares Outstanding
121,215.30
131,291.30
131,678.90
132,506.70
145,009.70
147,482.10
EPS (Diluted)
0.21
0.05
0.12
0.20
0.16
0.56
Diluted Shares Outstanding
121,215.30
131,291.30
134,524.00
135,846.20
147,939.30
149,899
EBITDA
10,905.00
6,558.00
9,357.00
25,326.00
46,619.00
46,464
Other Operating Expense
-
1,500.00
4,907.00
-
-
-
Non-Operating Interest Income
261.00
469.00
533.00
863.00
903.00
898
Minority Interest Expense
-
-
-
691.00
258.00
116

About Evotec

View Profile
Address
Manfred Eigen Campus
Hamburg Hamburg 22419
Germany
Employees -
Website http://evotec.com
Updated 07/08/2019
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.